Next Article in Journal
Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age
Next Article in Special Issue
Profile and Outcomes of Hospitalized COVID-19 Patients during the Prevalence of the Omicron Variant According to the Brazilian Regions: A Retrospective Cohort Study from 2022
Previous Article in Journal
Different Safety Pattern of an Inactivated SARS-CoV-2 Vaccine (CoronaVac®) According to Age Group in a Pediatric Population from 3 to 17 Years Old, in an Open-Label Study in Chile
Previous Article in Special Issue
Effectiveness of Mix-and-Match Vaccination in Preventing SARS-CoV-2 Omicron Variant Infection in Taiwan: A Test-Negative Control Study
 
 
vaccines-logo
Article Menu

Article Menu

Article

Article Versions Notes

Vaccines 2023, 11(10), 1527; https://doi.org/10.3390/vaccines11101527
Action Date Notes Link
article xml file uploaded 26 September 2023 13:15 CEST Original file -
article xml uploaded. 26 September 2023 13:15 CEST Update https://www.mdpi.com/2076-393X/11/10/1527/xml
article pdf uploaded. 26 September 2023 13:15 CEST Version of Record https://www.mdpi.com/2076-393X/11/10/1527/pdf
article supplementary file uploaded. 26 September 2023 13:15 CEST - https://www.mdpi.com/2076-393X/11/10/1527#supplementary
article html file updated 26 September 2023 13:16 CEST Original file https://www.mdpi.com/2076-393X/11/10/1527/html
Back to TopTop